AUTL:NSD-Autolus Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.14

Change

-0.08 (-1.90)%

Market Cap

USD 0.31B

Volume

0.55M

Avg Analyst Target

USD 14.50 (+250.24%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Autolus Therapeutics plc (AUTL) Stock Analysis:
Based on the Autolus Therapeutics plc stock forecasts from 2 analysts, the average analyst target price for Autolus Therapeutics plc is USD 14.50 over the next 12 months. Autolus Therapeutics plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Autolus Therapeutics plc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Autolus Therapeutics plc’s stock price was USD 4.14. Autolus Therapeutics plc’s stock price has changed by -0.41% over the past week, -1.30% over the past month and -53.27% over the last year.

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dua ...Read More

Company Website : https://www.autolus.com

Address : Forest House, London, United Kingdom, W12 7RZ

Employees : 376

Fiscal Year End : September

Currency: USD

Country : USA

Technical Indicators

Beta : 1.45

52 Week High : 9.12

Short Ratio : 4.00

52 Week Low : 4.11

Shorted Shares : 2,739,286

200 Day Moving Average : 6.10

Shorted Shares Previous Month : 2,317,780

50 Day Moving Average : 5.77

Shares Held By Insiders : 25.23%

Short Percentage : 3.62%

Shares Held by Institutions : 59.76%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

 USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

 USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

 USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

 USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

 USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

 USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

 USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

 USD17.76B N/A N/A

ETFs Containing AUTL

Symbol Name Weight Mer Price(Change) Market Cap
HOML UBS ETRACS Monthly Reset .. 8.77 % 0.85 %

N/A

 USD2.82M
PEZ Invesco DWA Consumer Cycl.. 3.64 % 0.60 %

-1.45 (-1.76%)

 USD0.20B
NAIL Direxion Daily Homebuilde.. 2.48 % 1.00 %

-6.61 (-7.77%)

 USD0.41B
ZEUS:CA BMO Shiller Select US Ind.. 1.40 % 0.73 %

N/A

 USD9.21M
DFAT Dimensional U.S. Targeted.. 0.55 % 0.34 %

-0.85 (-1.79%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.23% 33% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.23% 33% F 15% F
Trailing 12 Months  
Capital Gain -53.27% 49% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.27% 49% F 21% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.31% 6% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.31% 6% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 29.46% 86% B 58% F
Risk Adjusted Return -92.73% 3% F 1% F
Market Capitalization 0.31B 57% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.05 67% D+ 56% F
Price / Cash Flow Ratio -2.66 30% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -59.51% 48% F 25% F
Return on Invested Capital -61.94% 37% F 13% F
Return on Assets -33.53% 32% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.00 43% F 29% F
Short Percent 3.62% 57% F 42% F
Beta 1.45 39% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector